{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007746","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.206234+00:00","generated_at":"2026-06-16T00:22:02.318663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GlycoMimetics Q1 cash $65M; uproleselan Phase 3 trial on track for H1 2024 survival trigger","bullets":["Cash and equivalents $65.0M as of March 31, 2023, up from $47.9M at Dec 31, 2022; raised $28.7M via ATM.","R&D expenses fell to $5.4M from $9.6M YoY on lower clinical trial costs after Phase 3 enrollment completed.","Phase 3 uproleselan study continues; final overall survival event trigger projected within first half of 2024.","Cash runway expected to fund operations into late Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007746","json":"https://secwatch.observer/filing/0001558370-23-007746.json","markdown":"https://secwatch.observer/filing/0001558370-23-007746.md","text":"https://secwatch.observer/filing/0001558370-23-007746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/0001558370-23-007746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/glyc-20230503x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:22:02.318663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5637ecb762dd4acc9e1922bee7701026a23b71cf","claim":"CRESCENT BIOPHARMA, INC. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 3, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/0001558370-23-007746-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}